Throughout the globe,diabetes mellitus（DM） is increasing in incidence with limited therapies presently available to prevent or resolve the significant complications of this disorder.DM impacts multiple organs and af...Throughout the globe,diabetes mellitus（DM） is increasing in incidence with limited therapies presently available to prevent or resolve the significant complications of this disorder.DM impacts multiple organs and affects all components of the central and peripheral nervous systems that can range from dementia to diabetic neuropathy.The mechanistic target of rapamycin（m TOR） is a promising agent for the development of novel regenerative strategies for the treatment of DM.m TOR and its related signaling pathways impact multiple metabolic parameters that include cellular metabolic homeostasis,insulin resistance,insulin secretion,stem cell proliferation and differentiation,pancreatic β-cell function,and programmed cell death with apoptosis and autophagy.m TOR is central element for the protein complexes m TOR Complex 1（m TORC1） and m TOR Complex 2（m TORC2） and is a critical component for a number of signaling pathways that involve phosphoinositide 3-kinase（PI 3-K）,protein kinase B（Akt）,AMP activated protein kinase（AMPK）,silent mating type information regulation 2 homolog 1（Saccharomyces cerevisiae）（SIRT1）,Wnt1 inducible signaling pathway protein 1（WISP1）,and growth factors.As a result,m TOR represents an exciting target to offer new clinical avenues for the treatment of DM and the complications of this disease.Future studies directed to elucidate the delicate balance m TOR holds over cellular metabolism and the impact of its broad signaling pathways should foster the translation of these targets into effective clinical regimens for DM.展开更多
目的:探讨胰岛素样生长因子-1受体(insulinlike growth factor type 1 receptor,IGF-1R)、胰岛素样生长因子-1(insulin-like growth factor type 1,IGF-1)表达与临床病理特征之间的关系.方法:采用免疫组织化学的方法检测IGF-1R、IGF-1...目的:探讨胰岛素样生长因子-1受体(insulinlike growth factor type 1 receptor,IGF-1R)、胰岛素样生长因子-1(insulin-like growth factor type 1,IGF-1)表达与临床病理特征之间的关系.方法:采用免疫组织化学的方法检测IGF-1R、IGF-1在70例胃癌组织及部分相应癌旁组织中的表达,结合患者的性别、年龄、肿瘤大小、部位、分化程度、Borrmann分型、浸润深度、淋巴结转移和TNM分期等临床病理参数进行综合分析.结果:胃癌组织和癌旁组织中IGF-1R、IGF-1蛋白阳性表达分别为39例(55.71%)、8例(25.00%)和37例(52.86%)、5例(15.63%),差别有统计学意义(P<0.05);IGF-1R在低分化组阳性表达与中高分化组阳性表达两组间比较差异有统计学差异(P<0.05,χ2=4.124);IGF-1R、IGF-1在T1组、T2组、T3组、T4组阳性表达四组间有统计学差异(P<0.05);IGF-1R、IGF-1在无淋巴结转移组与有淋巴结转移组中阳性表达,两者间比较有显著统计学差异(P<0.05);IGF-1R、IGF-1在Ⅰ+Ⅱ期与Ⅲ+Ⅳ组内阳性表达两组间表达比较差异有显著统计学差异(P<0.05);IGF-1R阳性表达与患者的性别、年龄、肿瘤大小、部位及Borrmann分型均无明显相关(P>0.05).IGF-1阳性表达与患者的性别、年龄、肿瘤大小、部位、分化程度及Borrmann分型均无明显相关(P>0.05).经Spearman秩相关分析,IGF-1R与IGF-1在胃癌组织的表达呈正相关(r=0.310,P<0.01).结论:IGF-1R、IGF-1在胃癌组织中存在着过表达,在评估胃癌的发生、发展中有一定的临床价值.IGF-1R表达水平与肿瘤组织分化程度、浸润深度、淋巴结有无转移、TNM分期有关,IGF-1表达水平与肿瘤浸润深度、淋巴结有无转移、TNM分期有关.IGF-1R与IGF-1在胃癌组织中的表达呈正相关性,两者在胃癌的发生发展中起协同作用,未来可能会成为胃部肿瘤新型标志物.展开更多
基金supported by American Diabetes Association,American Heart Association,NIH NIEHS,NIH NIA,NIH NINDS,and NIH ARRA
文摘Throughout the globe,diabetes mellitus（DM） is increasing in incidence with limited therapies presently available to prevent or resolve the significant complications of this disorder.DM impacts multiple organs and affects all components of the central and peripheral nervous systems that can range from dementia to diabetic neuropathy.The mechanistic target of rapamycin（m TOR） is a promising agent for the development of novel regenerative strategies for the treatment of DM.m TOR and its related signaling pathways impact multiple metabolic parameters that include cellular metabolic homeostasis,insulin resistance,insulin secretion,stem cell proliferation and differentiation,pancreatic β-cell function,and programmed cell death with apoptosis and autophagy.m TOR is central element for the protein complexes m TOR Complex 1（m TORC1） and m TOR Complex 2（m TORC2） and is a critical component for a number of signaling pathways that involve phosphoinositide 3-kinase（PI 3-K）,protein kinase B（Akt）,AMP activated protein kinase（AMPK）,silent mating type information regulation 2 homolog 1（Saccharomyces cerevisiae）（SIRT1）,Wnt1 inducible signaling pathway protein 1（WISP1）,and growth factors.As a result,m TOR represents an exciting target to offer new clinical avenues for the treatment of DM and the complications of this disease.Future studies directed to elucidate the delicate balance m TOR holds over cellular metabolism and the impact of its broad signaling pathways should foster the translation of these targets into effective clinical regimens for DM.
文摘目的:探讨胰岛素样生长因子-1受体(insulinlike growth factor type 1 receptor,IGF-1R)、胰岛素样生长因子-1(insulin-like growth factor type 1,IGF-1)表达与临床病理特征之间的关系.方法:采用免疫组织化学的方法检测IGF-1R、IGF-1在70例胃癌组织及部分相应癌旁组织中的表达,结合患者的性别、年龄、肿瘤大小、部位、分化程度、Borrmann分型、浸润深度、淋巴结转移和TNM分期等临床病理参数进行综合分析.结果:胃癌组织和癌旁组织中IGF-1R、IGF-1蛋白阳性表达分别为39例(55.71%)、8例(25.00%)和37例(52.86%)、5例(15.63%),差别有统计学意义(P<0.05);IGF-1R在低分化组阳性表达与中高分化组阳性表达两组间比较差异有统计学差异(P<0.05,χ2=4.124);IGF-1R、IGF-1在T1组、T2组、T3组、T4组阳性表达四组间有统计学差异(P<0.05);IGF-1R、IGF-1在无淋巴结转移组与有淋巴结转移组中阳性表达,两者间比较有显著统计学差异(P<0.05);IGF-1R、IGF-1在Ⅰ+Ⅱ期与Ⅲ+Ⅳ组内阳性表达两组间表达比较差异有显著统计学差异(P<0.05);IGF-1R阳性表达与患者的性别、年龄、肿瘤大小、部位及Borrmann分型均无明显相关(P>0.05).IGF-1阳性表达与患者的性别、年龄、肿瘤大小、部位、分化程度及Borrmann分型均无明显相关(P>0.05).经Spearman秩相关分析,IGF-1R与IGF-1在胃癌组织的表达呈正相关(r=0.310,P<0.01).结论:IGF-1R、IGF-1在胃癌组织中存在着过表达,在评估胃癌的发生、发展中有一定的临床价值.IGF-1R表达水平与肿瘤组织分化程度、浸润深度、淋巴结有无转移、TNM分期有关,IGF-1表达水平与肿瘤浸润深度、淋巴结有无转移、TNM分期有关.IGF-1R与IGF-1在胃癌组织中的表达呈正相关性,两者在胃癌的发生发展中起协同作用,未来可能会成为胃部肿瘤新型标志物.
